Diwakar Davar, MBBS, MSc
Enriched profileAssociate Professor of Medicine; Clinical Director, Melanoma and Skin Cancer Program; Vice-Chief/Associate Chief, Academic Affairs, Division of Hematology-Oncology · UPMC Hillman Cancer Center
Diwakar Davar is Associate Professor of Medicine; Clinical Director, Melanoma and Skin Cancer Program; Vice-Chief/Associate Chief, Academic Affairs, Division of Hematology-Oncology at UPMC Hillman Cancer Center. OpenAlex indexes 333 publications with 6,346 citations (h-index 31); ClinicalTrials.gov lists 17 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Diwakar Davar is Associate Professor of Medicine at UPMC Hillman Cancer Center / University of Pittsburgh. The public record shows 333 publications with 6,346 citations (h-index 31), centered on Hepatobiliary Cancer, Kidney Cancer / RCC, Lung Cancer (NSCLC/SCLC). It also documents an investigator role on 17 registered clinical trials, industry payments reported by 22 companies, 1 NIH-funded awards (2021–2025).
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Hepatobiliary Cancer
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 40 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 1 Study of the Safety and Tolerability of CTX-10726
Sponsor: Compass Therapeutics
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Sponsor: Diwakar Davar
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202510 payments$15,161openpaymentsdata.cms.gov ↗
- Immunocore LimitedProgram year20258 payments
- Genmab U.S., Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
38.5%Corticosteroid38.5%Hydrocortisone100%Part D<11 patientsMetabolism & gastrointestinal
28%Corticosteroid28%Prednisone100%Part D≥24 patientsHormonal (systemic)
17.5%l-Thyroxine17.5%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
Fred Hutchinson Cancer Center
FY2026$829,054U01CA271407 - Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
Fred Hutchinson Cancer Center
FY2025$1,190,547U01CA271407 - Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
University of Pittsburgh at Pittsburgh
FY2025$481,846R01CA257265
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.
Journal for immunotherapy of cancer
Clinical Trial2026 - Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.
Clinical cancer research
Article2026 - Advancing ICOS agonism in solid tumors: lessons from INDUCE-1.
Journal for immunotherapy of cancer
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/diwakar-davar-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/diwakar-davar-253b244b
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Diwakar-Davar
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/story.php
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/emedeventsofficial/p/DDxxHhNzSLX
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Instagram
instagram.com/p/Cx8bAF3Mxu6
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗
- Board certified
Internal Medicine (ABIM)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - Board certified
Medical Oncology (ABIM)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Associate Professor of Medicine
University of Pittsburgh School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗ - Clinical Director
Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗ - Associate Chief/Vice-Chief
Academic Affairs, Division of Hematology-Oncology, University of Pittsburgh
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →upmc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.dom.pitt.edu ↗
Media & interviews
press, podcasts and appearances- Oncology Peer-Spectives podcast
Episode 139, discussion of nutrition science in cancer (sucralose study) with host Robert A. Figlin
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologynewscentral.com ↗ - OncoDaily feature
commentary on three Nature Medicine trials showing fecal microbiota transplant (FMT) boosts immune checkpoint inhibitor activity across RCC, NSCLC, and melanoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - UPMC news feature
"Fecal Transplant Boosts Cancer Immunotherapy" covering Davar/Zarour Science publication on FMT reversing anti-PD-1 resistance in melanoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →upmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Udai Kammula, MD
UPMC Hillman Cancer Center
Amer Zureikat, MD
UPMC Hillman Cancer Center
Antoinette Wozniak, MD
UPMC Hillman Cancer Center
Mounzer Agha, MD
UPMC Hillman Cancer Center